- ImpediMed (IPD) has secured a national purchasing agreement with a large U.S. oncology care network for the prevention of lymphedema
- This agreement gives 1200 physicians at 470 cancer treatment locations across the U.S., access to ImpediMed’s SOZO digital health platform
- SOZO is a highly-advanced non-invasive bioimpedance spectroscopy device that helps detect and manage patients with secondary lympedema
- The platform will be used during a Lymphedema Prevention Program
- This program is aimed at educating health care workers and patients about detecting and managing lymphedema before it becomes serious
- ImpediMed is trading flat with shares trading for 4.8 cents each
ImpediMed (IPD) has secured a national purchasing agreement with a large U.S. oncology care network for the prevention of lymphedema.
This agreement gives 1200 physicians at 470 cancer treatment locations across the U.S., access to ImpediMed’s SOZO digital health platform through a Lymphedema Prevention Program.
The Lymphedema Prevention Program uses ImpediMed’s Test, Trigger, Treat protocol for early detection of cancer-related lymphedema. Routine lymphedema testing of cancer survivors uses the company’s SOZO device with BIS (LDex) technology.
“This purchasing agreement opens the door to thousands of patients and their care providers to participate in the Lymphoedema Prevention Program,” Managing Director and CEO Richard Carreon said.
The Lymphedema Prevention Program aims to educate healthcare providers and patients that with the right protocols in place, lymphedema can be detected and managed before it becomes a chronic condition.
“We expect SOZO sales in this network to begin immediately and to expand throughout the upcoming year,” Richard added.
ImpediMed received FDA clearance for its SOZO technology in November 2019.
SOZO is a highly-advanced, non-invasive bioimpedance spectroscopy (BIS) device that assesses patients with secondary lymphedema to determine fluid status and tissue composition is less than 30 seconds.
Currently, one in three at-risk cancer survivors will develop secondary lymphedema-related to their cancer treatment. This costs the U.S. healthcare system approximately $7 billion each year.
ImpediMed is trading flat with shares trading for 4.8 cents each at 2:27 pm AEDT.